Who makes CVL006 in combination with DS-8201?

CVL006 in combination with DS-8201 is developed by Convalife (Shanghai) Co., Ltd..

What development phase is CVL006 in combination with DS-8201 in?

CVL006 in combination with DS-8201 is in Phase 1.

Last reviewed 2026-05-15 · How we verify

CVL006 in combination with DS-8201

Convalife (Shanghai) Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	CVL006 in combination with DS-8201
Also known as	CVL006（B006 Injection）、DS-8201a（Trastuzumab deruxtecan）
Sponsor	Convalife (Shanghai) Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

CVL006 Combination Therapy in Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CVL006 in combination with DS-8201 CI brief — competitive landscape report
CVL006 in combination with DS-8201 updates RSS · CI watch RSS
Convalife (Shanghai) Co., Ltd. portfolio CI